AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.

Trial Profile

AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AFFIRM
  • Sponsors Medivation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2017 Results of exploratory analysis assessing benefits of enzalutamide through FACT-P in mCRPC clinical trials (AFFIRM and PREVAIL), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 07 Feb 2017 Results of a post hoc analysis evaluating association between prostate-specific antigen (PSA) levels and clinical outcomes published in the Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top